EQT Private Equity and QIAGEN announced on October 21, 2026 a recommended all-cash takeover at 46.50 euros per share, an enterprise value of about 10.8 billion euros (about $12.1 billion). The price is 40.3% above QIAGEN's closing share price on July 8, the last trading day before reports of private equity interest, yet the deal is not expected to close until mid-2027. For owners thinking about a sale, the length of that road and the conditions along it deserve as much attention as the premium.
EQT's offer comes through Crown NL Bidco B.V., a vehicle indirectly controlled by the EQT XI fund, with Abu Dhabi Investment Authority's Luxinva and CPP Investments as co-investors. It is a voluntary public takeover offer under German law, paired with a U.S. tender offer, and QIAGEN's supervisory and managing boards unanimously approved the agreement. QIAGEN has about 5,400 employees across more than 35 locations, and EQT has said the company will keep its name and brand.
Enterprise value is the price of the whole business, including debt, rather than only the shares. Here it includes roughly $1.1 billion of net debt, which is why the release gives a total of about $12.1 billion and not an equity figure. The financing is committed from EQT's equity and a group of banks that includes Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole and UniCredit, and the offer has no financing condition. In plain terms, QIAGEN's shareholders are not being asked to bet on whether the buyer can raise the money.
The 40.3% premium is calculated against the July 8 closing price of 33.15 euros, the last trading day before press reports of private equity interest. QIAGEN also cites a 46.9% premium to the three-month volume-weighted average price (the average price over that period, weighted by how much stock traded at each level) through the same date. Both figures use a cutoff before the reports, because once takeover interest leaks, the share price starts to reflect the possibility of a deal.
Private company owners have no share price to anchor on, but the principle carries over. A premium or a multiple only means something relative to a stated starting point, so it is worth asking which valuation, earnings measure, and date the buyer is using. An offer described as a strong multiple of next year's projected earnings can look quite different when restated against trailing results.
EQT's offer is subject to a minimum acceptance threshold of 50% of QIAGEN's share capital plus one share, shareholder approval at an extraordinary general meeting of the steps that would give EQT full ownership, merger control and foreign investment clearances, and a separate board implementation decision. Those post-closing measures matter because they would let EQT acquire the shares of holders who did not tender; the boards must proceed if at least 80% of votes cast approve them, and may still proceed below that level if they judge it in the company's best interest.
Each condition is a point where a deal can slow down or change shape. A buyer can be fully committed and well financed, and the seller can still wait on an outside party such as a regulator or a counterparty.
EQT expects closing in mid-2027, roughly eight to nine months after the announcement. If the deal has not closed within 10 months because regulatory approvals are pending, QIAGEN may pay an interim dividend of up to $0.47 per share, which would not be deducted from the 46.50 euro offer price. That provision gives shareholders some cash during a long wait without reducing what they are ultimately paid.
Compare this with Salesforce's agreement, announced a day earlier, to buy Braze for $47.50 per share in cash, an enterprise value of about $5.66 billion. Salesforce expects that deal to close in its fiscal 2028, which begins February 1, 2027. Both are cash transactions, and in both the seller's outcome depends on approvals that sit outside either party's control.

Most private company sales are smaller and faster than a public takeover, but the same questions apply. A higher offer that needs months of regulatory review, third-party consents, or lender approvals can leave a seller worse off than a slightly lower offer that closes in 60 days. During the gap, the owner still runs the business under restrictions in the purchase agreement, employees and customers hear rumors, and a change in markets or in the company's results can reopen the negotiation.
Business owners can price this directly. If two offers differ by 5% and one closes four months later, the question is whether the extra payment compensates for four months of uncertainty, and for what it would cost if the deal failed and the company returned to market with a delay on its record.
The QIAGEN offer shows a pattern that applies well beyond public companies: the headline premium is only one input, and the conditions and time to closing determine how much of it a seller collects and when. Owners comparing offers should weigh price, certainty, and timing together, and ask for each to be spelled out before choosing a buyer.